Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 6Refractory Solid Tumors 3Advanced Solid Tumors 3Solid Tumors 2Mesothelioma 2Unspecified Adult Solid Tumor 1Solitary Fibrous Tumor, Pleural 1Sarcoma 1SOLID TUMORS 1Relapsed Pediatric Solid Tumor 1Prostatic Neoplasms 1Pediatric Solid Tumors 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Cisplatin 6Pemetrexed 5cediranib 3Chemotherapy, Adjuvant 3Radiotherapy 2Neoadjuvant Therapy 2Gemcitabine 2vatalanib 1rilotumumab 1pembrolizumab 1belinostat 1Watchful Waiting 1Vinorelbine 1Talc 1Sorafenib 1Semaxinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pharmacogenomic Testing 1Methotrexate 1Immunoenzyme Techniques 1Gefitinib 1Erlotinib Hydrochloride 1Dihematoporphyrin Ether 1Dasatinib 1Capecitabine 1Bevacizumab 1ARQ 197 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solitary Fibrous Tumor, Pleural × Sorafenib × Other solid neoplasm × Clear all
NCT00107432 2013-06-05

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

National Cancer Institute (NCI)

Phase 2 Completed
44 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡